494 related articles for article (PubMed ID: 30691684)
1. Exploiting epigenetically mediated changes: Acute myeloid leukemia, leukemia stem cells and the bone marrow microenvironment.
Kogan AA; Lapidus RG; Baer MR; Rassool FV
Adv Cancer Res; 2019; 141():213-253. PubMed ID: 30691684
[TBL] [Abstract][Full Text] [Related]
2. Roles of the bone marrow niche in hematopoiesis, leukemogenesis, and chemotherapy resistance in acute myeloid leukemia.
Wang A; Zhong H
Hematology; 2018 Dec; 23(10):729-739. PubMed ID: 29902132
[TBL] [Abstract][Full Text] [Related]
3. Convergent epigenetic evolution drives relapse in acute myeloid leukemia.
Nuno K; Azizi A; Koehnke T; Lareau C; Ediriwickrema A; Corces MR; Satpathy AT; Majeti R
Elife; 2024 Apr; 13():. PubMed ID: 38647535
[TBL] [Abstract][Full Text] [Related]
4. Role of Microenvironment in Resistance to Therapy in AML.
Tabe Y; Konopleva M
Curr Hematol Malig Rep; 2015 Jun; 10(2):96-103. PubMed ID: 25921386
[TBL] [Abstract][Full Text] [Related]
5. The Role of Hypoxic Bone Marrow Microenvironment in Acute Myeloid Leukemia and Future Therapeutic Opportunities.
Bruno S; Mancini M; De Santis S; Monaldi C; Cavo M; Soverini S
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34202238
[TBL] [Abstract][Full Text] [Related]
6. Acute myeloid leukemia transforms the bone marrow niche into a leukemia-permissive microenvironment through exosome secretion.
Kumar B; Garcia M; Weng L; Jung X; Murakami JL; Hu X; McDonald T; Lin A; Kumar AR; DiGiusto DL; Stein AS; Pullarkat VA; Hui SK; Carlesso N; Kuo YH; Bhatia R; Marcucci G; Chen CC
Leukemia; 2018 Mar; 32(3):575-587. PubMed ID: 28816238
[TBL] [Abstract][Full Text] [Related]
7. A CXCR4 antagonist leads to tumor suppression by activation of immune cells in a leukemia-induced microenvironment.
Han AR; Lee JY; Kim HJ; Min WS; Park G; Kim SH
Oncol Rep; 2015 Dec; 34(6):2880-8. PubMed ID: 26398122
[TBL] [Abstract][Full Text] [Related]
8. Vitamin D Receptor Controls Cell Stemness in Acute Myeloid Leukemia and in Normal Bone Marrow.
Paubelle E; Zylbersztejn F; Maciel TT; Carvalho C; Mupo A; Cheok M; Lieben L; Sujobert P; Decroocq J; Yokoyama A; Asnafi V; Macintyre E; Tamburini J; Bardet V; Castaigne S; Preudhomme C; Dombret H; Carmeliet G; Bouscary D; Ginzburg YZ; de Thé H; Benhamou M; Monteiro RC; Vassiliou GS; Hermine O; Moura IC
Cell Rep; 2020 Jan; 30(3):739-754.e4. PubMed ID: 31968250
[TBL] [Abstract][Full Text] [Related]
9. Mesenchymal stromal cells derived from acute myeloid leukemia bone marrow exhibit aberrant cytogenetics and cytokine elaboration.
Huang JC; Basu SK; Zhao X; Chien S; Fang M; Oehler VG; Appelbaum FR; Becker PS
Blood Cancer J; 2015 Apr; 5(4):e302. PubMed ID: 25860293
[TBL] [Abstract][Full Text] [Related]
10. Crosstalk between DNA methylation and hypoxia in acute myeloid leukaemia.
Humphries S; Bond DR; Germon ZP; Keely S; Enjeti AK; Dun MD; Lee HJ
Clin Epigenetics; 2023 Sep; 15(1):150. PubMed ID: 37705055
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic Abnormalities in Acute Myeloid Leukemia and Leukemia Stem Cells.
Xu J; Hang X; Wu B; Chen C; Liu Y
Adv Exp Med Biol; 2019; 1143():173-189. PubMed ID: 31338820
[TBL] [Abstract][Full Text] [Related]
12. Epigenetics in acute myeloid leukemia.
Plass C; Oakes C; Blum W; Marcucci G
Semin Oncol; 2008 Aug; 35(4):378-87. PubMed ID: 18692688
[TBL] [Abstract][Full Text] [Related]
13. Targeting the bone marrow microenvironment in acute leukemia.
Karantanou C; Godavarthy PS; Krause DS
Leuk Lymphoma; 2018 Nov; 59(11):2535-2545. PubMed ID: 29431560
[TBL] [Abstract][Full Text] [Related]
14. Biology and relevance of human acute myeloid leukemia stem cells.
Thomas D; Majeti R
Blood; 2017 Mar; 129(12):1577-1585. PubMed ID: 28159741
[TBL] [Abstract][Full Text] [Related]
15. TIM-3 as a therapeutic target for malignant stem cells in acute myelogenous leukemia.
Kikushige Y; Akashi K
Ann N Y Acad Sci; 2012 Aug; 1266():118-23. PubMed ID: 22901263
[TBL] [Abstract][Full Text] [Related]
16. Newly diagnosed adult AML and MPAL patients frequently show clonal residual hematopoiesis.
Fernandez C; Santos-Silva MC; López A; Matarraz S; Jara-Acevedo M; Ciudad J; Gutierrez ML; Sánchez ML; Salvador-Osuna C; Berruezo MJ; Díaz-Arias JÁ; Palomo-Hernández AM; Colado E; González N; Gallardo D; Asensio A; García-Sánchez R; Saldaña R; Cerveró C; Carboné-Bañeres A; Gutierrez O; Orfao A
Leukemia; 2013 Nov; 27(11):2149-56. PubMed ID: 23579575
[TBL] [Abstract][Full Text] [Related]
17. The bone-marrow niche in MDS and MGUS: implications for AML and MM.
Ghobrial IM; Detappe A; Anderson KC; Steensma DP
Nat Rev Clin Oncol; 2018 Apr; 15(4):219-233. PubMed ID: 29311715
[TBL] [Abstract][Full Text] [Related]
18. A potential area of use for immune checkpoint inhibitors: Targeting bone marrow microenvironment in acute myeloid leukemia.
Aru B; Pehlivanoğlu C; Dal Z; Dereli-Çalışkan NN; Gürlü E; Yanıkkaya-Demirel G
Front Immunol; 2023; 14():1108200. PubMed ID: 36742324
[TBL] [Abstract][Full Text] [Related]
19. Molecular alterations in bone marrow mesenchymal stromal cells derived from acute myeloid leukemia patients.
von der Heide EK; Neumann M; Vosberg S; James AR; Schroeder MP; Ortiz-Tanchez J; Isaakidis K; Schlee C; Luther M; Jöhrens K; Anagnostopoulos I; Mochmann LH; Nowak D; Hofmann WK; Greif PA; Baldus CD
Leukemia; 2017 May; 31(5):1069-1078. PubMed ID: 27833093
[TBL] [Abstract][Full Text] [Related]
20. IGFBP7 Induces Differentiation and Loss of Survival of Human Acute Myeloid Leukemia Stem Cells without Affecting Normal Hematopoiesis.
Verhagen HJMP; van Gils N; Martiañez T; van Rhenen A; Rutten A; Denkers F; de Leeuw DC; Smit MA; Tsui ML; de Vos Klootwijk LLE; Menezes RX; Çil M; Roemer MGM; Vermue E; Heukelom S; Zweegman S; Janssen JJWM; Ossenkoppele GJ; Schuurhuis GJ; Smit L
Cell Rep; 2018 Dec; 25(11):3021-3035.e5. PubMed ID: 30540936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
